 |
|
Effect of Abnormal Thyroid Function on the Severity of Graves' Ophthalmopathy
Mark F. Prummel, MD;
Wilmar M. Wiersinga, MD, PhD;
Maarten Ph. Mounts, MD;
Leo Koornneef, MD, PhD;
Arie Berghout, MD;
Ruth van der Gaag, PhD
Arch Intern Med. 1990;150(5):1098-1101.
Abstract
• Many clinicians have the impression that treatment of thyroid dysfunction ameliorates ophthalmopathy in Graves' disease. The aim of our study was to relate thyroid function to the severity of Graves' ophthalmopathy. We studied 90 patients with Graves' ophthalmopathy and Graves' hyperthyroidism in whom severity of Graves' ophthalmopathy and thyroid function (regardless of antithyroid treatment) were assessed when referred to our institution. Patients were assigned to four groups (A through D) with increasingly severe Graves' ophthalmopathy using Total Eye Score based on the NOSPECS classification. The percentage of dysthyroid patients in each group was determined: group A had 23% dysthyroid patient (5); group B, 32% (9); group C, 61% (14); and group D, 47% (8). More dysthyroid patients were in the groups with severe Graves' ophthalmopathy. We also compared the severity of Graves' ophthalmopathy between euthyroid (n = 54) and dysthyroid (n = 36) patients: euthyroid patients had less proptosis (19.9±3.5 vs 20.8±3.4 mm), better visual acuity (0.93±0.17 vs 0.88±0.18), and lower Total Eye Score (8.6±6.6 vs 10.6±6.6). We conclude that dysthyroidism is associated with more severe Graves' ophthalmopathy. Our findings suggest that meticulous control of thyroid function also during antithyroid treatment is important in the management of Graves' ophthalmopathy.
(Arch Intern Med. 1990;150:1098-1101)
Author Affiliations
From the Department of Endocrinology (Drs Prummel, Wiersinga, and Berghout), and the Orbital Center (Drs Mourits and Koornneef), Academic Medical Center, University of Amsterdam; and the Department of Ophthalmo-Immunology, Netherlands Ophthalmic Research Institute (Dr van der Gaag), Amsterdam, the Netherlands.
Footnotes
Accepted for publication November 8,1989.
Read in part before the 63rd meeting of the American Thyroid Association, Montreal, Canada, September 27,1988.
Reprint requests to Department of Endocrinology, F5-258, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands (Dr Prummel).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
3.3.10 Graves' ophthalmopathy and dermopathy
Wiersinga
Oxford Textbook of Endocrinology and Diabetes 2011;2:med-9780199235292-chapter-med-9780199235292-chapter.
ABSTRACT
| FULL TEXT
Altered Ganglioside Expression Modulates the Pathogenic Mechanism of Thyroid-Associated Ophthalmopathy by Increase in Hyaluronic Acid
Kook et al.
IOVS 2011;52:264-273.
ABSTRACT
| FULL TEXT
Graves' Orbitopathy Activation after Radioactive Iodine Therapy with and without Steroid Prophylaxis
Vannucchi et al.
J. Clin. Endocrinol. Metab. 2009;94:3381-3386.
ABSTRACT
| FULL TEXT
Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO
Bartalena et al.
Eur J Endocrinol 2008;158:273-285.
FULL TEXT
Methylprednisolone pulse therapy for patients with moderately severe Graves' orbitopathy: a prospective, randomized, placebo-controlled study
van Geest et al.
Eur J Endocrinol 2008;158:229-237.
ABSTRACT
| FULL TEXT
Effects of Total Thyroid Ablation Versus Near-Total Thyroidectomy Alone on Mild to Moderate Graves' Orbitopathy Treated with Intravenous Glucocorticoids
Menconi et al.
J. Clin. Endocrinol. Metab. 2007;92:1653-1658.
ABSTRACT
| FULL TEXT
Thyrotropin Receptor Autoantibodies Are Independent Risk Factors for Graves' Ophthalmopathy and Help to Predict Severity and Outcome of the Disease
Eckstein et al.
J. Clin. Endocrinol. Metab. 2006;91:3464-3470.
ABSTRACT
| FULL TEXT
The relation of Graves' ophthalmopathy to circulating thyroid hormone status
Kim et al.
Br J Ophthalmol 2004;88:72-74.
ABSTRACT
| FULL TEXT
Can contrast enhanced MRI predict the response of Graves' ophthalmopathy to orbital radiotherapy?
Ott et al.
Br. J. Radiol. 2002;75:514-517.
ABSTRACT
| FULL TEXT
Insights Into the Pathogenesis of Thyroid-Associated Orbitopathy: Evolving Rationale for Therapy
Kazim et al.
Arch Ophthalmol 2002;120:380-386.
FULL TEXT
Management of Graves' Ophthalmopathy: Reality and Perspectives
Bartalena et al.
Endocr Rev 2000;21:168-199.
ABSTRACT
| FULL TEXT
Graves' Ophthalmopathy: Is It Really Thyroid Disease?
FELDON
Arch Intern Med 1990;150:948-950.
ABSTRACT
|
